UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 000-55654 NUTRIBAND INC. (Exact name of registrant as specified in its charter) | Nevada | 81-1118176 | | --- | --- | | (State or oth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 000-55654 NUTRIBAND INC. (Exact name of registrant as specified in its charter) | NEVADA | 81-1118176 | | --- | --- | | (Stat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 000-55654 NUTRIBAND INC. (Exact name of registrant as specified in its charter) | NEVADA | 81-1118176 | | --- | --- | | (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 000-55654 NUTRIBAND INC. (Exact name of registrant as specified in its charter) | NEVADA | 81-1118176 | | --- | --- | | (State or other j ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 31, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 000-55654 NUTRIBAND INC. (Exact name of registrant as specified in its charter) | Nevada | 81-1118176 | | --- | --- | | (State or oth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 000-55654 NUTRIBAND INC. (Exact name of registrant as specified in its charter) | NEVADA | 81-1118176 | | --- | --- | | (Stat ...

Revenue Performance - Total revenue for the three months ended July 31, 2021, was $213,739, a 153% increase compared to $84,450 for the same period in 2020[13]. - Total revenue for the six months ended July 31, 2021, reached $647,227, up 218% from $203,814 in the same period of 2020[13]. - Revenue from the sale of goods for the six months ended July 31, 2021, was $541,251, up from $120,770 in 2020, indicating an increase of 348%[41]. - For the three months ended July 31, 2021, total revenue was $213,739, compared to $84,450 for the same period in 2020, representing a growth of 152%[41]. - For the six months ended July 31, 2021, the company generated revenue of $647,227, up from $203,814 in the same period in 2020, resulting in a gross margin of $291,621 compared to $11,938 in 2020[121]. Net Loss and Expenses - Net loss for the three months ended July 31, 2021, was $519,923, compared to a net loss of $225,869 for the same period in 2020, representing a 130% increase in losses[13]. - Net loss for the six months ended July 31, 2021, was $835,880, an increase of 31% from a net loss of $638,063 in the same period of 2020[13]. - Selling, general and administrative expenses for the three months ended July 31, 2021, were $509,219, a significant increase from $193,331 in the same period of 2020[13]. - Selling, general and administrative expenses for the six months ended July 31, 2021, were $1,088,827, an increase from $355,248 in the same period in 2020, primarily due to non-cash consulting expenses and expenses from Active Intelligence[122]. Assets and Liabilities - Total current assets as of July 31, 2021, were $606,750, compared to $314,188 as of January 31, 2021, reflecting a 93% increase[11]. - Total assets increased to $10,163,555 as of July 31, 2021, from $9,927,419 as of January 31, 2021, marking a 2.4% growth[11]. - Total liabilities as of July 31, 2021, were $2,847,489, slightly up from $2,815,473 as of January 31, 2021[11]. - Stockholders' equity increased to $7,316,066 as of July 31, 2021, from $7,111,946 as of January 31, 2021, indicating a 2.9% rise[11]. Cash Flow and Financing - Cash used in operating activities was $367,944 for the six months ended July 31, 2021, compared to $313,652 for the same period in 2020, indicating a 17% increase in cash outflow[18]. - The company reported net cash provided by financing activities of $569,605 for the six months ended July 31, 2021, compared to $342,719 for the same period in 2020, reflecting a 66% increase in financing cash flow[18]. - Cash and cash equivalents at the end of the period were $304,258, significantly up from $39,248 at the end of the same period in 2020, marking an increase of over 675%[18]. - The company incurred stock-based compensation expenses of $225,000 for the six months ended July 31, 2021, compared to $38,000 in the same period in 2020, which is an increase of approximately 493%[18]. Acquisitions and Investments - The acquisition of 4P Therapeutics LLC for $2,250,000 included a royalty of 6% on all revenue generated from the abuse deterrent intellectual property developed by 4P Therapeutics[22]. - The company acquired net assets valued at $7,418,073 from Pocono Coated Products and Active Intelligence, including $6,085,180 in common stock issued and a note payable of $1,332,893[59]. - The company acquired Advanced Health Brands, Inc. for 1,250,000 shares of common stock valued at $2,500,000[89]. - The company purchased assets from Pocono Coated Products for $6,000,000 in common stock and a $1,500,000 promissory note[97]. Regulatory and Compliance - The company recognizes revenue based on the five criteria established under Topic 606, ensuring compliance with revenue recognition standards[36]. - The company has implemented plans to alleviate substantial doubt about its ability to continue as a going concern, including increasing sales commitments and reducing overhead expenses[31]. - The company has established additional monitoring controls over financial statements and added qualified accounting personnel to reduce reliance on third-party consultants[144]. - The SEC accepted a settlement offer from the company and its officers for violations related to inaccurate statements in SEC filings, resulting in cease-and-desist orders[150]. Product Development and Market Position - The company is focused on developing transdermal pharmaceutical products, which are currently in the preclinical stage and require FDA approval before marketing[24]. - The company is seeking FDA approval for its transdermal pharmaceutical products, which is a time-consuming and expensive process[111]. - The company has suspended its pharmaceutical product development operations due to a lack of funds, which is critical for the development of transdermal systems for pharmaceuticals[154]. - The company has not completed the development of its lead product, the abuse deterrent fentanyl transdermal system, and lacks any marketable product in the United States[156]. Leadership and Governance - Nutriband Inc. is represented by Gareth Sheridan as the Chief Executive Officer and Gerald Goodman as the Chief Financial Officer, indicating leadership stability[164]. - The CEO's annual salary is set at $42,000, increasing to $170,000 upon raising at least $2,500,000 in equity financing[92]. Miscellaneous - The company recorded no bad debt expense for doubtful accounts related to accounts receivable for the six months ended July 31, 2021, and 2020[42]. - The company has no long-term contractual obligations and can terminate contracts at any time[110]. - The company has filed various certifications including Section 302 and Section 906 by the Chief Executive Officer and Chief Financial Officer, ensuring compliance with regulatory requirements[31][32][33]. - The report includes XBRL documents which facilitate the analysis and sharing of financial data, enhancing transparency and accessibility for investors[101].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 000-55654 NUTRIBAND INC. Indicate by check mark whether the registrant has submitted electronically every Interactive Data ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 31, 2021 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 000-55654 NUTRIBAND INC. (Exact name of registrant as specified in its charter) | Nevada | 81-1118176 | | --- | --- | | (State or oth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 000-55654 NUTRIBAND INC. (Exact name of registrant as specified in its charter) | NEVADA | 81-1118176 | | --- | --- | | ( ...